A Phase 1 Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL15/sIL-15Ra)) Alone and in Combination With PDR001 in Adults With Metastatic Cancers

Trial Profile

A Phase 1 Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL15/sIL-15Ra)) Alone and in Combination With PDR001 in Adults With Metastatic Cancers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs Interleukin-15 (Primary)
  • Indications Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma
  • Focus Adverse reactions
  • Sponsors Admune Therapeutics; Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 25 Apr 2017 Planned End Date changed from 1 Dec 2016 to 1 Sep 2018.
    • 25 Apr 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top